… ProQR Appoints John Maraganore, PhD, as Strategic Advisor to … & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … if any,” said Daniel A. de Boer, Founder and CEO of ProQR. “As the founding CEO of Alnylam, he built and led one …
… ProQR In-licenses Worldwide Rights to Ophthalmology Drug … said Daniel A. de Boer, chief executive officer of ProQR. “By acquiring the rights to QR-1123, we have … will be made in equity and others in cash or equity at ProQR’s discretion, and royalties on net sales of 20% through …
… ProQR to Present Axiomer RNA Editing Platform Technology at … & CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … Platenburg, co-founder and Chief Innovation Officer of ProQR. “With this approach disease-causing mutations can be …
… ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten … für die Augenheilkunde von Ionis Pharmaceuticals ProQR erhält die exklusive weltweite Lizenz für IONIS-RHO-2.5 … LEIDEN (Niederlande), Oct. 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), ein Unternehmen, das …
… ProQR to Present at 3rd Annual Evercore ISI Virtual … will be accessible from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under ‘ Events ’. The archived webcast will …
… ProQR Announces Additional Sepofarsen Illuminate Trial … top-line announcement in February 2022 that Illuminate , ProQR’s pivotal Phase 2/3 trial of sepofarsen in CEP290 … scheme by the EMA. About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of …